Complementary effects of sirolimus-eluting stents and glycoprotein IIb/IIIa inhibitors for percutaneous coronary intervention in diabetic patients: one-year follow up of a single-centre registry

Heart. 2006 Aug;92(8):1155-6. doi: 10.1136/hrt.2005.079780.
No abstract available

Publication types

  • Letter

MeSH terms

  • Coronary Restenosis / prevention & control*
  • Diabetic Angiopathies / prevention & control*
  • Disease-Free Survival
  • Drug Combinations
  • Drug Implants
  • Eptifibatide
  • Follow-Up Studies
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Peptides / administration & dosage
  • Platelet Aggregation Inhibitors / administration & dosage*
  • Platelet Glycoprotein GPIIb-IIIa Complex / antagonists & inhibitors*
  • Sirolimus / administration & dosage*
  • Stents*
  • Tirofiban
  • Tyrosine / administration & dosage
  • Tyrosine / analogs & derivatives

Substances

  • Drug Combinations
  • Drug Implants
  • Immunosuppressive Agents
  • Peptides
  • Platelet Aggregation Inhibitors
  • Platelet Glycoprotein GPIIb-IIIa Complex
  • Tyrosine
  • Tirofiban
  • Eptifibatide
  • Sirolimus